AstraZeneca, the U.K.-Swedish pharmaceutical giant, on Tuesday announced a plan to invest some $50 billion in the U.S. in a move hailed by the Trump administration — though much of what it is announcing it’s already announced before.

AstraZeneca said Tuesday it's planning to invest $50 billion in expanding its manufacturing and research presence in the U.S. by 2030, as worries about tariffs loom over the industry.